Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Published:2021-10 Issue:10308 Volume:398 Page:1344-1357
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Felip Enriqueta,Altorki Nasser,Zhou Caicun,Csőszi Tibor,Vynnychenko Ihor,Goloborodko Oleksandr,Luft Alexander,Akopov Andrey,Martinez-Marti Alex,Kenmotsu Hirotsugu,Chen Yuh-Min,Chella Antonio,Sugawara Shunichi,Voong David,Wu Fan,Yi Jing,Deng Yu,McCleland Mark,Bennett Elizabeth,Gitlitz Barbara,Wakelee Heather

Funder

F Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

General Medicine

Reference35 articles.

1. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades;Lu;Cancer Manag Res,2019

2. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer;Ghysen;Curr Opin Oncol,2019

3. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer;Goldstraw;J Thorac Oncol,2016

4. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Postmus;Ann Oncol,2017

5. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer;Arriagada;N Engl J Med,2004

Cited by 887 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review;International Immunopharmacology;2024-11

2. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

3. Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC;Scientific Reports;2024-09-13

4. Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials;Clinical and Translational Oncology;2024-09-12

5. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11